Kai Lipinski

Kai Lipinski currently serves as Chief Scientific Officer (CSO) at Recipharm since April 2022. Prior to this role, Kai held various leadership positions at Vibalogics between June 2010 and April 2022, including Chief Scientific Officer, Head of Process Development, and Head of Cell Culture and Virus Production. From January 2007 to June 2010, Kai worked as a Principal Scientist at RecipharmCobra Biologics, focusing on upstream process development for virus/vaccine and mammalian protein expression projects. Kai's early career at Cobra Therapeutics/ML Laboratories spanned from 1998 to 2006, where responsibilities included the development of targeted adenoviral vectors for cancer gene therapy, with emphasis on tumor-selective promoters. Educational background includes a PostDoc in Transcriptional Regulation from the University of Duisburg-Essen, a PhD in Transcriptional Regulation by Adenoviral E1A proteins from the same university, and a BSc/MSc in Biology from The University of Bonn and Ruhr University Bochum. Kai Lipinski possesses a strong foundation in Virology, Cell Culture, and Molecular Biology.